Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

Adele K. Fielding, Susan M. Richards, Rajesh Chopra, Hillard M. Lazarus, Mark R Litzow, Georgina Buck, I. Jill Durrant, Selina M. Luger, David I. Marks, Ian M. Franklin, Andrew K. McMillan, Martin S. Tallman, Jacob M. Rowe, Anthony H. Goldstone

Research output: Contribution to journalArticle

444 Citations (Scopus)

Abstract

Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse. We examined the outcome of 609 adults with recurring ALL, all of whom were previously treated on the Medical Research Council (MRC) UKALL12/ECOG2993 study, where the overall survival (OS) of newly diagnosed patients is 38% (95% confidence interval [CI] = 36%-41%) at 5 years. By contrast, OS at 5 years after relapse was 7% (95% CI = 4%-9%). Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients younger than 20 years vs OS of 3% in patients older than 50 years; 2P < .001) and short duration of first remission (CR1) (OS of 11% in those with a CR1 of more than 2 years versus OS of 5% in those with a CR1 of less than 2 years; 2P < .001). Treatment received in CR1 did not influence outcome after relapse. In a very highly selected subgroup of patients who were able to receive HSCT after relapse, some were long-term survivors. We conclude from a large, unselected series with mature follow-up that most adults with recurring ALL, whatever their prior treatment, cannot be rescued using currently available therapies. Prevention of recurrence is the best strategy for long-term survival in this disease.

Original languageEnglish (US)
Pages (from-to)944-950
Number of pages7
JournalBlood
Volume109
Issue number3
DOIs
StatePublished - Feb 1 2007

Fingerprint

Salvaging
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Biomedical Research
Recurrence
Survival
Confidence Intervals
Salvage Therapy
Survivors
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G., ... Goldstone, A. H. (2007). Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 109(3), 944-950. https://doi.org/10.1182/blood-2006-05-018192

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. / Fielding, Adele K.; Richards, Susan M.; Chopra, Rajesh; Lazarus, Hillard M.; Litzow, Mark R; Buck, Georgina; Durrant, I. Jill; Luger, Selina M.; Marks, David I.; Franklin, Ian M.; McMillan, Andrew K.; Tallman, Martin S.; Rowe, Jacob M.; Goldstone, Anthony H.

In: Blood, Vol. 109, No. 3, 01.02.2007, p. 944-950.

Research output: Contribution to journalArticle

Fielding, AK, Richards, SM, Chopra, R, Lazarus, HM, Litzow, MR, Buck, G, Durrant, IJ, Luger, SM, Marks, DI, Franklin, IM, McMillan, AK, Tallman, MS, Rowe, JM & Goldstone, AH 2007, 'Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study', Blood, vol. 109, no. 3, pp. 944-950. https://doi.org/10.1182/blood-2006-05-018192
Fielding, Adele K. ; Richards, Susan M. ; Chopra, Rajesh ; Lazarus, Hillard M. ; Litzow, Mark R ; Buck, Georgina ; Durrant, I. Jill ; Luger, Selina M. ; Marks, David I. ; Franklin, Ian M. ; McMillan, Andrew K. ; Tallman, Martin S. ; Rowe, Jacob M. ; Goldstone, Anthony H. / Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. In: Blood. 2007 ; Vol. 109, No. 3. pp. 944-950.
@article{24d00a1c147342a2a441010ae2949438,
title = "Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study",
abstract = "Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse. We examined the outcome of 609 adults with recurring ALL, all of whom were previously treated on the Medical Research Council (MRC) UKALL12/ECOG2993 study, where the overall survival (OS) of newly diagnosed patients is 38{\%} (95{\%} confidence interval [CI] = 36{\%}-41{\%}) at 5 years. By contrast, OS at 5 years after relapse was 7{\%} (95{\%} CI = 4{\%}-9{\%}). Factors predicting a good outcome after salvage therapy were young age (OS of 12{\%} in patients younger than 20 years vs OS of 3{\%} in patients older than 50 years; 2P < .001) and short duration of first remission (CR1) (OS of 11{\%} in those with a CR1 of more than 2 years versus OS of 5{\%} in those with a CR1 of less than 2 years; 2P < .001). Treatment received in CR1 did not influence outcome after relapse. In a very highly selected subgroup of patients who were able to receive HSCT after relapse, some were long-term survivors. We conclude from a large, unselected series with mature follow-up that most adults with recurring ALL, whatever their prior treatment, cannot be rescued using currently available therapies. Prevention of recurrence is the best strategy for long-term survival in this disease.",
author = "Fielding, {Adele K.} and Richards, {Susan M.} and Rajesh Chopra and Lazarus, {Hillard M.} and Litzow, {Mark R} and Georgina Buck and Durrant, {I. Jill} and Luger, {Selina M.} and Marks, {David I.} and Franklin, {Ian M.} and McMillan, {Andrew K.} and Tallman, {Martin S.} and Rowe, {Jacob M.} and Goldstone, {Anthony H.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1182/blood-2006-05-018192",
language = "English (US)",
volume = "109",
pages = "944--950",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

AU - Fielding, Adele K.

AU - Richards, Susan M.

AU - Chopra, Rajesh

AU - Lazarus, Hillard M.

AU - Litzow, Mark R

AU - Buck, Georgina

AU - Durrant, I. Jill

AU - Luger, Selina M.

AU - Marks, David I.

AU - Franklin, Ian M.

AU - McMillan, Andrew K.

AU - Tallman, Martin S.

AU - Rowe, Jacob M.

AU - Goldstone, Anthony H.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse. We examined the outcome of 609 adults with recurring ALL, all of whom were previously treated on the Medical Research Council (MRC) UKALL12/ECOG2993 study, where the overall survival (OS) of newly diagnosed patients is 38% (95% confidence interval [CI] = 36%-41%) at 5 years. By contrast, OS at 5 years after relapse was 7% (95% CI = 4%-9%). Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients younger than 20 years vs OS of 3% in patients older than 50 years; 2P < .001) and short duration of first remission (CR1) (OS of 11% in those with a CR1 of more than 2 years versus OS of 5% in those with a CR1 of less than 2 years; 2P < .001). Treatment received in CR1 did not influence outcome after relapse. In a very highly selected subgroup of patients who were able to receive HSCT after relapse, some were long-term survivors. We conclude from a large, unselected series with mature follow-up that most adults with recurring ALL, whatever their prior treatment, cannot be rescued using currently available therapies. Prevention of recurrence is the best strategy for long-term survival in this disease.

AB - Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse. We examined the outcome of 609 adults with recurring ALL, all of whom were previously treated on the Medical Research Council (MRC) UKALL12/ECOG2993 study, where the overall survival (OS) of newly diagnosed patients is 38% (95% confidence interval [CI] = 36%-41%) at 5 years. By contrast, OS at 5 years after relapse was 7% (95% CI = 4%-9%). Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients younger than 20 years vs OS of 3% in patients older than 50 years; 2P < .001) and short duration of first remission (CR1) (OS of 11% in those with a CR1 of more than 2 years versus OS of 5% in those with a CR1 of less than 2 years; 2P < .001). Treatment received in CR1 did not influence outcome after relapse. In a very highly selected subgroup of patients who were able to receive HSCT after relapse, some were long-term survivors. We conclude from a large, unselected series with mature follow-up that most adults with recurring ALL, whatever their prior treatment, cannot be rescued using currently available therapies. Prevention of recurrence is the best strategy for long-term survival in this disease.

UR - http://www.scopus.com/inward/record.url?scp=33846869976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846869976&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-05-018192

DO - 10.1182/blood-2006-05-018192

M3 - Article

C2 - 17032921

AN - SCOPUS:33846869976

VL - 109

SP - 944

EP - 950

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -